HLA-B27 · ulcerative colitis · spine

HLA-B27 and Ulcerative Colitis: Screening for Spinal Involvement

HLA-B27 sharply raises the risk of spinal disease in ulcerative colitis: in pooled cohorts, carriers had a relative risk of 22.17 for ankylosing spondylitis. Across 71 studies of inflammatory bowel disease, 10% of patients had sacroiliitis and 3% ankylosing spondylitis, yet axial symptoms are rarely asked about.

Axial involvement in inflammatory bowel disease is common, gene-sorted and rarely asked about. Neither the gastroenterology visit nor the spine workup is built to catch it.

HLA-B27 is the sharpest available risk marker for axial disease in ulcerative colitis, and the HLA-B27 ulcerative colitis patient is seldom screened for it. In a meta-analysis of ulcerative colitis cohorts, carriage conferred a relative risk of 22.17 for ankylosing spondylitis, and 68.29% of those who developed it were carriers against 31.71% who were not. Because just three of the pooled studies recorded carrier status, the confidence around that figure is broad.

In the video Your Gut Is Reaching Your Spine, Chapter 11 of The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, the gut-to-spine evidence is sorted into tiers: inflammatory spread that is established, and a disc microbiome hypothesis that is not. For the physician, the established tier is the actionable one. It defines whom to ask, what to order, where to refer and what to document.

How common is spine involvement in ulcerative colitis and IBD?

Across 71 studies, prevalence in inflammatory bowel disease was 10% for sacroiliitis, 3% for ankylosing spondylitis and 13% for peripheral arthritis. Only three incidence studies exist, with follow-up windows of 5 to 30 years, so prevalence is well described and rate of onset is not. A 52-study synthesis of 352,454 patients reported at least one extraintestinal manifestation in 24%, with subtype figures of 27% for ulcerative colitis and 35% for Crohn’s disease drawn from different pooled subsets, and axial involvement at comparable rates in both.

The arrow also runs in reverse. Of 108 patients with ankylosing spondylitis and no known bowel disease who underwent ileocolonoscopy, 40 had inflammatory lesions and 17 had a diagnosable disease: Crohn’s in 12, intestinal tuberculosis in 4 and ulcerative colitis in 1. Among those scoped purely as screening, 17.6% showed abnormalities, predominantly erosions and ulcers. That series was retrospective, single-center, symptom-enriched and unadjusted for NSAID exposure.

The miss is structural rather than a knowledge gap. Gastroenterology follow-up is organized around the bowel, the spine pathway around the disc, and neither visit template carries the question that links them.

How does HLA-B27 link gut and spine inflammation?

HLA-B27 transgenic rats develop gut and joint inflammation; raised without microbial colonization they develop neither, while skin and genital lesions still appear. In human ileal biopsies, interleukin-23 is overexpressed in ankylosing spondylitis without a matching rise in interleukin-17. Spondylitis gut biopsies also show inflammasome expression roughly tenfold above controls (NLRP3 fold induction 22.2 versus 2.33), with NLRP3 correlating with spinal disease activity at r = 0.28, a modest association.

The management implication is concrete. An interleukin-17A antagonist that performs in axial disease was ineffective in Crohn’s disease, with outcomes worse than placebo, in a phase II trial in which 18 of 59 patients discontinued early. In a patient carrying both diagnoses, a therapy chosen for the spine can work against the bowel, which means the axial diagnosis should be made and shared before that choice.

Imaging findings and the antibiotic request

The lumbar MRI rarely settles the question. Modic changes are present in about 6% of asymptomatic people and a median 43% of those with back pain; type 1 carries an odds ratio of 4.01 for pain, while unspecified Modic change carries 1.62 with an interval spanning one. Patients who have read about disc bacteria may request antibiotics. The Norwegian multicenter trial prespecified a minimal important difference of 4 points and found −1.6, with −2.3 in type 1 and −0.1 in type 2, and drug-related adverse events of 56% against 34%. The 2026 Australian trial found a twelve-month pain difference of 0.06 on a 0-to-10 scale, though only six of 170 participants had type 1 changes alone.

What Measura measures, and what it does not

Measura [Cardiometabolic and Autonomic Health Analysis] does not image the sacroiliac joints, scope the bowel, sequence stool or perform HLA typing; those remain with the ordering physician and specialists. What the protocol contributes is a documented terrain in the same patient:

• Laboratory panels for the metabolic markers of insulin resistance that accompany metaflammation.
• Bioimpedance body composition for fat and lean compartments that BMI conflates.
• Autonomic nervous system testing and heart rate variability for autonomic balance in patients whose nocturnal pain fragments sleep.

None of these diagnoses spondyloarthritis. They document the upstream drivers of a breached barrier: acellular carbohydrates that deplete short-chain fatty acid producers, industrial seed oils, sleep lost to night pain, and metaflammation beneath all of them. In a pilot of surgical patients with disc disease, 20 per subgroup, stool showed depleted short-chain fatty acid producers while CRP ran elevated. How results are structured for the chart is covered in interpreting the report.

A workflow for the inflammatory bowel disease panel

1. Add an inflammatory back pain screen to bowel disease visits: nocturnal pain in the second half of the night, morning stiffness beyond half an hour, improvement with activity and worsening with rest.
2. For positive screens, order HLA-B27 and route to rheumatology for sacroiliac assessment rather than repeating lumbar imaging.
3. Communicate an axial diagnosis to gastroenterology before biologic selection.
4. Document the metabolic and autonomic terrain at baseline and at reassessment.
5. Build the screen into standing orders so it does not depend on which specialist the patient saw that day.

The same malabsorbing bowel drives the deficiency discussed in vitamin D screening and falls risk. Specialty-specific uses are outlined in specialty applications, and the complete evidence file is the Chapter 11 Deep Dive.

Frequently asked questions

What proportion of IBD patients have axial spondyloarthritis?

Pooled prevalence across 71 studies was 10% for sacroiliitis and 3% for ankylosing spondylitis, with 13% peripheral arthritis. Incidence is poorly characterized, with only three studies reporting it over follow-up of 5 to 30 years. Axial involvement ran at similar rates in Crohn’s disease and ulcerative colitis in a larger synthesis. Criteria for which patients to evaluate are summarized in selection criteria.

Should HLA-B27 be ordered in every patient with ulcerative colitis?

A history-triggered approach is the practical option. Carriage conferred a relative risk of 22.17 for ankylosing spondylitis in ulcerative colitis, but only three pooled studies reported carrier status. An inflammatory back pain history gives a clear trigger for ordering and referral. HLA typing is not a Measura test and is ordered through the treating physician. The protocol logic is addressed in clinical rationale.

Does interleukin-17 blockade affect the bowel in patients with both conditions?

In Crohn’s disease, an interleukin-17A antagonist was ineffective, with outcomes worse than placebo, in a phase II trial of 59 patients, 18 of whom discontinued early. Interleukin-23 is overexpressed in the spondylitis gut without interleukin-17. Coordinating the choice with gastroenterology is the prudent course. Structured sharing of results across services is described in getting results into the record.

Are antibiotics indicated for Modic changes in patients with IBD?

Current trials do not support routine use. The Norwegian trial found −1.6 points against a minimal important difference of 4, and the 2026 Australian trial found a twelve-month pain difference of 0.06, with adverse events in 40.0% against 23.5%. A disc without blood supply is a poor target for oral therapy. Longitudinal follow-up between visits is covered in chronic care and between-visit monitoring.

Can Measura testing detect enteropathic spondyloarthritis?

No. Measura does not perform imaging, endoscopy, stool analysis or HLA typing. It documents the metabolic, body-composition and autonomic terrain in the same patient, which complements the rheumatology and gastroenterology workup rather than replacing any part of it. Common questions about scope and ordering are answered in physician questions.

What does a positive HLA-B27 mean if you have ulcerative colitis?

It marks a much higher chance of spinal arthritis. In pooled ulcerative colitis cohorts, carriers had a relative risk of 22.17 for ankylosing spondylitis, and 68.29% of those who developed it were carriers. Only three of the pooled studies recorded carrier status, so the exact size of the risk is uncertain. A positive result with inflammatory back pain belongs with rheumatology for a sacroiliac assessment.

What are the signs of inflammatory back pain?

Four features point to it: pain in the second half of the night, morning stiffness lasting longer than half an hour, pain that improves with activity, and pain that worsens with rest. In a patient with inflammatory bowel disease, a positive screen calls for HLA-B27 testing and a rheumatology referral for sacroiliac assessment rather than another lumbar scan. The screen belongs in every bowel disease visit.

Can ankylosing spondylitis point to hidden bowel disease?

Yes, the link runs both ways. Of 108 patients with ankylosing spondylitis and no known bowel disease who had an ileocolonoscopy, 40 had inflammatory lesions and 17 had a diagnosable disease, most often Crohn’s. The series was retrospective, single-center and weighted toward patients with symptoms, so treat it as a reason to ask spondylitis patients about their bowels, not as a rate.

References

• Lin, A., Tan, Y., Chen, J., Liu, X., & Wu, J. (2023). Development of ankylosing spondylitis in patients with ulcerative colitis: A systematic meta-analysis. PLoS One, 18(8), e0289021. https://doi.org/10.1371/journal.pone.0289021
• Karreman, M. C., Luime, J. J., Hazes, J. M. W., & Weel, A. E. A. M. (2017). The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: A systematic review and meta-analysis. Journal of Crohn’s & Colitis, 11(5), 631–642. https://doi.org/10.1093/ecco-jcc/jjw199
• Kilic, Y., Kamal, S., Jaffar, F., Sriranganathan, D., Quraishi, M. N., & Segal, J. P. (2024). Prevalence of extraintestinal manifestations in inflammatory bowel disease: A systematic review and meta-analysis. Inflammatory Bowel Diseases, 30(2), 230-239. https://doi.org/10.1093/ibd/izad061
• Ahn, S. M., Kim, Y.-G., Bae, S.-H., Lim, D.-H., Hong, S., Park, S. H., Lee, C.-K., & Yoo, B. (2017). Ileocolonoscopic findings in patients with ankylosing spondylitis: A single center retrospective study. The Korean Journal of Internal Medicine, 32(5), 916-922. https://doi.org/10.3904/kjim.2015.313
• Taurog, J. D., Richardson, J. A., Croft, J. T., Simmons, W. A., Zhou, M., Fernández-Sueiro, J. L., Balish, E., & Hammer, R. E. (1994). The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. The Journal of Experimental Medicine, 180(6), 2359–2364. https://doi.org/10.1084/jem.180.6.2359
• Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., Karczewski, J., Pezous, N., Bek, S., Bruin, G., Mellgard, B., Berger, C., Londei, M., Bertolino, A. P., Tougas, G., & Travis, S. P. L. (2012). Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut, 61(12), 1693–1700. https://doi.org/10.1136/gutjnl-2011-301668
• Guggino, G., Mauro, D., Rizzo, A., Alessandro, R., Raimondo, S., Bergot, A.-S., Rahman, M. A., Ellis, J. J., Milling, S., Lories, R., Elewaut, D., Brown, M. A., Thomas, R., & Ciccia, F. (2021). Inflammasome activation in ankylosing spondylitis is associated with gut dysbiosis. Arthritis & Rheumatology, 73(7), 1189-1199. https://doi.org/10.1002/art.41644
• Bråten, L. C. H., Rolfsen, M. P., Espeland, A., Wigemyr, M., Aßmus, J., Froholdt, A., Haugen, A. J., Marchand, G. H., Kristoffersen, P. M., Lutro, O., Randen, S., Wilhelmsen, M., Winsvold, B. S., Kadar, T. I., Holmgard, T. E., Vigeland, M. D., Vetti, N., Nygaard, Ø. P., Lie, B. A., … Zwart, J.-A. (2019). Efficacy of antibiotic treatment in patients with chronic low back pain and Modic changes (the AIM study): double blind, randomised, placebo controlled, multicentre trial. BMJ, 367, l5654. https://doi.org/10.1136/bmj.l5654
• Brinjikji, W., Diehn, F. E., Jarvik, J. G., Carr, C. M., Kallmes, D. F., Murad, M. H., & Luetmer, P. H. (2015). MRI findings of disc degeneration are more prevalent in adults with low back pain than in asymptomatic controls: A systematic review and meta-analysis. AJNR. American Journal of Neuroradiology, 36(12), 2394–2399. https://doi.org/10.3174/ajnr.A4498
• Cicuttini, F. M., Wluka, A. E., Pan, F., O’Sullivan, R., Leder, K., Cheng, A. C., & Urquhart, D. M. (2026). Efficacy of antibiotics for chronic low back pain with disc herniation: a randomized clinical trial. JAMA Network Open, 9(5), e2612848. https://doi.org/10.1001/jamanetworkopen.2026.12848

Related reading

• Vitamin D Screening: Who Has an Indication and What Falls Risk Adds
• Blood-Brain Barrier Dysfunction: Screening the Metabolic Drivers
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.